Plain-English translation of NCT06680739 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two immune-boosting medications— and —can help treat advanced colorectal and endometrial cancers that have spread or returned after other treatments. You'll be randomly assigned to receive either alone or both medications together, depending on the genetic characteristics of your tumor. The researchers will track how well the treatment works and monitor your safety throughout the study.
Standard chemotherapy treatments don't work well enough for many patients with these cancers, especially after previous treatments have failed. This medication works by helping your own immune system recognize and fight cancer cells, and researchers believe combining two different immune therapies might be more effective than using just one.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication(s) every 4 weeks at the study center. Every 8 weeks, you'll have imaging scans (CT or MRI) to check how your cancer is responding. You'll also have regular blood tests to monitor your health and watch for side effects. The study involves a single center location and will continue until your cancer progresses, you experience unacceptable side effects, or the research team determines it's time to stop.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Spain